BMS' last work with Stand Up To Cancer was a fall lung cancer PSA campaign with actor Common. Now the pharma is funding a lung cancer research team. (Photo by Paras Griffin/Getty Images)

BMS, Mi­rati fund new Stand Up To Can­cer re­search teams, adding to list of phar­ma part­ner­ships

Stand Up To Can­cer is well-known for its celebri­ty con­nec­tions and gala fundrais­ing events, but in phar­ma and biotech, it’s al­so known as a re­search part­ner. Its two re­cent­ly added teams part­ner with Bris­tol My­ers Squibb on lung can­cer dis­par­i­ties and Mi­rati Ther­a­peu­tics on KRAS can­cers.

The new ad­di­tions aug­ment Stand Up To Can­cer’s phar­ma part­ner­ships, which in­clude 13 teams in its Cat­a­lyst pro­gram. The Cat­a­lyst pro­gram launched in 2016, spon­sored ini­tial­ly by BMS, Mer­ck and Roche’s Genen­tech, to pair in­dus­try fund­ing and ma­te­ri­als with sci­en­tif­ic part­ners with the am­bi­tion to ac­cel­er­ate can­cer re­search, de­tec­tion and treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.